| Bioactivity | Daratumumab (Anti-Human CD38) is the first-in-class human-specific anti-CD38 monoclonal antibody (IgG1). Daratumumab has anti-multiple myeloma (MM) effect. Daratumumab impairs MM cell adhesion, which results in an increased sensitivity of MM to proteasome inhibition[1][2]. |
| Invitro | Daratumumab (Anti-Human CD38) induces potent Ab-dependent cellular cytotoxicity in CD38-expressing lymphoma- and MM-derived cell lines[2]. |
| In Vivo | Daratumumab (i.p.; 0.5 mg/kg; 14 d after challenge with Daudi-luc cells) inhibits outgrowth of CD38-expressing tumor cells in mouse xenograft tumor models[2]. Animal Model: |
| Name | Daratumumab |
| CAS | 945721-28-8 |
| Appearance | Liquid |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Ghose J, Viola D, et al. Daratumumab induces CD38 internalization and impairs myeloma cell adhesion. Oncoimmunology. 2018;7(10):e1486948. Published 2018 Jul 23. [2]. de Weers M, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol. 2011;186(3):1840-1848. |